<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Anderson EMS Pocket Medic</title>
    <link rel="icon" href="../favicon.ico" type="image/png" />
    <link rel="stylesheet" href="../Environmental.css" />
    <link rel="stylesheet" href="OrgExposure.css" />
  </head>
  <body>
    <a href="../../../index.html" class="header-link">
      <div class="header">
        <h1>Anderson EMS Pocket Medic</h1>
      </div>
    </a>

    <div class="MainBody">
      <h2>
        Acetylcholinesterase Inhibitor Exposure<br />
        (Organophosphates / Nerve Agents)
      </h2>

      <div class="InitialBody">
        <table class="StartTable">
          <thead>
            <tr>
              <th>History</th>
              <th>Signs and Symptoms</th>
              <th>Differential</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>
                • Substance<br /><br />
                • Time of ingestion or exposure<br /><br />
                • Route of exposure<br /><br />
                • Quantity of medication or toxin taken<br /><br />
                • Alcohol or other intoxicant taken<br /><br />
                • Past medical history<br /><br />
                • Medications<br /><br />
                • Decontamination performed<br /><br />
                • Treatment prior to arrival
              </td>
              <td>
                <strong>DUMBELLS</strong><br /><br />
                • <strong><u>D</u></strong
                >efecation / <strong><u>D</u></strong
                >iarrhea<br /><br />
                • <strong><u>U</u></strong
                >rination; increase, loss of control<br /><br />
                • <strong><u>M</u></strong
                >iosis (pupils constrict)/Muscle weakness/fasciculations<br /><br />
                • <strong><u>B</u></strong
                >ronchospasm, Bronchorrhea, Bradycardia (killer B’s)<br /><br />
                • <strong><u>E</u></strong
                >mesis<br /><br />
                • <strong><u>L</u></strong
                >acrimation<br /><br />
                • <strong><u>S</u></strong
                >alivation/Sweating
              </td>
              <td>
                • Nerve agent exposure (e.g. VX, Sarin, Soman, etc.)<br /><br />
                • Organophosphate exposure (pesticide)<br /><br />
                • Vesicant exposure (e.g. Mustard Gas, etc.)<br /><br />
                • Respiratory irritant exposure <br />(e.g. Hydrogen Sulfide,
                Ammonia, Chlorine, etc.)
              </td>
            </tr>
          </tbody>
        </table>
        <p>
          <span class="yellowCenter">Estimated Level of Exposure</span>
          <br /><br />

          <img
            src="ExposureLevel.PNG"
            alt="Exposure Level Chart"
            style="
              display: block;
              margin-left: auto;
              margin-right: auto;
              max-width: 100%;
              height: auto;
              float: none;
              align-self: center;
              justify-self: center;
            "
          />
        </p>
        <h3 class="AllLevels">EMR & EMT</h3>
        <p>
          1. Assure scene is safe and the patient has been decontaminated if
          needed.<br /><br />
          2.
          <a
            href="../../General/UniversalSources/Universal.html"
            class="working-link"
            title="Universal Patient Care SOG"
            >UNIVERSAL PATIENT CARE</a
          >.<br /><br />
          3. Save all bottles, containers or labels for information without
          exposing rescuers.<br /><br />
          4. Relay information to incoming ambulance or call for intercept per
          <a
            href="../../General/InterceptCriteriaSources/Intercept.html"
            class="working-link"
            title="Intercept Criteria SOG"
            >INTERCEPT CRITERIA</a
          >.<br /><br />
          5. Contact <strong>Resource Hospital Medical Control</strong> for any
          multiple victim response so that CHEMPACK activation may be
          initiated.<br /><br />
          6. If available, administer via
          <a href="#" title="Coming Soon" class="placeholder-link"
            >AUTOINJECTOR ATROPINE/PRALIDOXIME</a
          >
          (Ex. Duodote, Mark 1). Repeat every 3-5 minutes until symptoms of
          SLUDGE subside, most importantly secretions
        </p>
        <h3 class="PARAMEDIC">Paramedic/PHRN</h3>
        <p>
          1. Continue <strong>EMR / EMT TREATMENT</strong>.<br /><br />
          2. If symptomatic, administer
          <a
            href="../../../DrugMaterial/AtropineFolder/Atropine.html"
            class="working-link"
            title="Atropine Med Page"
            >ATROPINE</a
          >
          <strong>2 mg IV or IM</strong>.<br /><br />
          3. Repeat
          <a
            href="../../../DrugMaterial/AtropineFolder/Atropine.html"
            class="working-link"
            title="Atropine Med Page"
            >ATROPINE</a
          >
          <strong>2-4 mg IV</strong> every 3-5 minutes until symptoms of SLUDGE
          subside, most importantly secretions.<br /><br />
          4. Establish IV access. Administer
          <strong>Isotonic IV Fluid</strong> to maintain SBP ≥ 90 mmHg or MAP ≥
          65 mmHg. Repeat fluid bolus as needed as long as lungs remain clear to
          maintain SBP ≥ 90 mmHg; maximum 2 liters.<br /><br />
          5. Apply cardiac monitor.<br /><br />
          6. If seizures occur, refer to
          <a
            href="../../AdultMedical/SeizureSources/Seizure.html"
            class="working-link"
            title="Seizure SOG"
            >SEIZURE / STATUS EPILEPTICUS</a
          >
          protocol.
        </p>
        <p>
          <span class="pearlsFormat"><strong>PEARLS</strong></span
          ><br /><br />
          • Continuous and ongoing patient reassessment is critical.<br /><br />
          • Clinical response to treatment is demonstrated by the drying of
          secretion and the easing of respiratory effort.<br /><br />
          • Initiation of and ongoing treatment should not be based upon heart
          rate or pupillary response.<br /><br />
          • Atropine is the primary antidote for organophosphate, carbamate, or
          nerve agent exposures, and repeated doses should be administered
          liberally to patients who exhibit signs and symptoms of exposure or
          toxicity.<br /><br />
          • Clinical effects of acetylcholinesterase inhibitor agents<br /><br />
          <span class="Indention">
            a. The clinical effects are caused by the inhibition of the enzyme
            acetylcholinesterase which allows excess acetylcholine to accumulate
            in the nervous system.<br /><br />
            b. The excess accumulated acetylcholine causes hyperactivity in
            muscles, glands, and nerves. </span
          ><br />
          • Organophosphates (certain Insecticides)<br /><br />
          <span class="Indention">
            a. Can be legally purchased by the general public.<br /><br />
            b. Organophosphates (e.g. pesticides) penetrate tissues and bind to
            the patient’s body fat producing a prolonged period of illness and
            ongoing toxicity even during aggressive treatment. </span
          ><br />
          • Nerve agents<br /><br />
          <span class="Indention">
            a. Traditionally classified as weapons of mass destruction (WMD).<br /><br />
            b. Not readily accessible to the general public.<br /><br />
            c. Extremely toxic and rapidly fatal with any route of exposure.<br /><br />
            d. GA (tabun), GB (sarin), GD (soman), GF, and VX are types of nerve
            agents and are WMDs.<br /><br />
            e. Nerve agents can persist in the environment and remain chemically
            toxic for a prolonged period of time.<br />
          </span>
        </p>

        <table class="EndTable">
          <thead>
            <tr>
              <th><strong>KEY DOCUMENTATION ELEMENTS </strong></th>
              <th><strong>PERTINENT ASSESSMENT FINDINGS </strong></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>
                • Time to recognize initial signs and symptoms<br /><br />
                • Number of repeated doses of atropine required for the
                secretions diminish and respirations to improve<br /><br />
                • Patient reassessments<br /><br />
                • Patient responses to therapeutic interventions<br /><br />
                • Measures taken to decontaminate the patient<br /><br />
                • Measures taken to protect clean environments from
                contamination
              </td>
              <td>
                • Signs and symptoms exhibited with the toxidromes of
                <strong>DUMBBELS</strong>
              </td>
            </tr>
          </tbody>
        </table>
        <table class="QMTable">
          <tr>
            <td><strong>QUALITY METRICS</strong><br /><br /></td>
          </tr>
          <tr>
            <td>• Recognition and appropriate treatment of patients</td>
          </tr>
        </table>
      </div>
    </div>
    <script src="https://code.jquery.com/jquery-3.7.1.min.js"></script>
    <script src="OrgExposure.js"></script>
  </body>
  <footer class="footer">
    <p>
      <img
        src="../../../LukiSoftLogo.png"
        alt="Field Triage Algorithm"
        style="
          display: block;
          margin-left: auto;
          margin-right: auto;
          width: 100px;
          height: auto;
          border-radius: 15px;
        "
      />

      &copy; 2025 LukiSoft. All rights reserved.
    </p>
  </footer>
</html>
